Workshop B: An Understanding of Insulin Resistance, Implications to MASH Pathophysiology
Time: 9:00 am
day: Pre Conf Workshop Day - Clinical & Regulatory Track
Details:
New treatment options are provided by a combination of incretins and insulin sensitizers
- Insulin sensitizing pharmacology impacts the underlying MASH pathology providing a new understanding of the underlying pathology
- Incretin treatments impact more than underlying obesity and also provide unique opportunities in combination with insulin sensitizers
- A round table discussion will discuss which features of the MASH pathology are most relevant to selection and assessment of treatment options and how to consider the potential for impact on hepatic and extrahepatic outcomes
